TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors

TriSalus Life Sciences, Inc.

Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.
Filing a Form 12b-25 for late 10-K due to errors in stock-based compensation and R&D expense timing.
Reaffirms 2025 guidance: >50% revenue growth, >20% OpEx reduction, positive EBITDA, positive cash flow H2 2025.
Cash $8.5M at Dec 31, plus $15M available under $50M OrbiMed credit facility.
Launched TriNav LV and TriGuide catheters; DELIVER program expanding addressable market to >$1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.